Literature DB >> 7539326

Modulation of cytokine-induced eosinophil infiltration by phosphodiesterase inhibitors.

V Lagente1, M P Pruniaux, J L Junien, I Moodley.   

Abstract

The effects of selective phosphodiesterase (PDE) isoenzyme inhibitors on eosinophil airway infiltration induced by intratracheal administration of recombinant human cytokines were investigated in the guinea pig. Recombinant human IL-5 and IL-8 elicited a concentration-dependent increase in the number of eosinophils in the bronchoalveolar lavage (BAL) fluid. In contrast, no effect was observed after intratracheal injection of recombinant human IL-3 or recombinant human RANTES. Pretreatment with the PDE IV inhibitors rolipram or Ro 20-1724 or the nonselective PDE inhibitor theophylline 1 h before intratracheal injection of IL-5 significantly reduced the number of eosinophils in the BAL fluid at 48 h. In contrast, the selective PDE III inhibitors milrinone and SK&F 94-836 and the PDE I/V inhibitor zaprinast did not inhibit the airway eosinophil infiltration induced by IL-5. Betamethasone also significantly inhibited the IL-5-induced eosinophil infiltration in BAL fluid. Administration of rolipram or betamethasone 1 h before IL-8 significantly reduced airway eosinophil infiltration. Because the selective PDE IV inhibitors markedly inhibited eosinophil infiltration in guinea pig airways induced by cytokines, it is suggested that PDE IV inhibitors have antiinflammatory effects in the airways and may be useful in the treatment of asthma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7539326     DOI: 10.1164/ajrccm.151.6.7539326

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  13 in total

Review 1.  Asthma therapy and its effect on airway remodelling.

Authors:  Rachid Berair; Christopher E Brightling
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

2.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

Review 3.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

4.  Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

Authors:  J L Ortiz; J M Vallés; M Martí-Cabrera; J Cortijo; E J Morcillo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

5.  Liver Tumor Microenvironment.

Authors:  Diamantis I Tsilimigras; Ioannis Ntanasis-Stathopoulos; Dimitrios Moris; Timothy M Pawlik
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 6.  Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma.

Authors:  Antonella Cammarota; Antonio D'Alessio; Tiziana Pressiani; Lorenza Rimassa; Nicola Personeni
Journal:  Drugs Aging       Date:  2021-06-21       Impact factor: 3.923

7.  Reduced airway hyperresponsiveness by phosphodiesterase 3 and 4 inhibitors in guinea-pigs.

Authors:  N Germain; E Boichot; J M Planquois; V Lagente
Journal:  Mediators Inflamm       Date:  1999       Impact factor: 4.711

8.  Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy.

Authors:  Martin Thelen; Kerstin Wennhold; Jonas Lehmann; Maria Garcia-Marquez; Sebastian Klein; Elena Kochen; Philipp Lohneis; Axel Lechner; Svenja Wagener-Ryczek; Patrick Sven Plum; Oscar Velazquez Camacho; David Pfister; Fabian Dörr; Matthias Heldwein; Khosro Hekmat; Dirk Beutner; Jens Peter Klussmann; Fabinshy Thangarajah; Dominik Ratiu; Wolfram Malter; Sabine Merkelbach-Bruse; Christiane Josephine Bruns; Alexander Quaas; Michael von Bergwelt-Baildon; Hans A Schlößer
Journal:  NPJ Precis Oncol       Date:  2021-06-16

Review 9.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007

10.  rAj-Tspin, a novel recombinant peptide from Apostichopus japonicus, suppresses the proliferation, migration, and invasion of BEL-7402 cells via a mechanism associated with the ITGB1-FAK-AKT pathway.

Authors:  Ping Yu; Rui Wu; Zunchun Zhou; Xin Zhang; Ruoshu Wang; Xueting Wang; Sen Lin; Jihong Wang; Li Lv
Journal:  Invest New Drugs       Date:  2020-09-28       Impact factor: 3.651

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.